Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia

NCT02078219 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

204

Enrollment

INDUSTRY

Sponsor class

Conditions

Gout and Hyperuricemia

Interventions

DRUG: RDEA3170
DRUG: Allopurinol
DRUG: Placebo

Sponsor

AstraZeneca

Collaborators

[object Object]